BR0115306A - Composto, prodroga, composição farmacêutica, agente para diminuir androgênio, método para a produção de um composto, e, sal diastereomérico - Google Patents
Composto, prodroga, composição farmacêutica, agente para diminuir androgênio, método para a produção de um composto, e, sal diastereoméricoInfo
- Publication number
- BR0115306A BR0115306A BR0115306-4A BR0115306A BR0115306A BR 0115306 A BR0115306 A BR 0115306A BR 0115306 A BR0115306 A BR 0115306A BR 0115306 A BR0115306 A BR 0115306A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- prodrug
- pharmaceutical composition
- producing
- lowering agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicinal Preparation (AREA)
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000351780 | 2000-11-17 | ||
JP2001247618 | 2001-08-17 | ||
JP2001336880 | 2001-11-01 | ||
PCT/JP2001/010002 WO2002040484A2 (en) | 2000-11-17 | 2001-11-16 | Novel imidazole derivatives, production method thereof and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR0115306A true BR0115306A (pt) | 2004-02-10 |
BR0115306B1 BR0115306B1 (pt) | 2013-12-24 |
Family
ID=27345219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0115306-4B1A BR0115306B1 (pt) | 2000-11-17 | 2001-11-16 | Derivado de imidazol, composição farmacêutica, métodos para a produção de um derivado de imidazol e de um composto oticamente ativo de um derivado de imidazol ou de um seu sal farmaceuticamente aceitável, composto, sal, e, sal diastereomérico |
Country Status (27)
Country | Link |
---|---|
US (1) | US7141598B2 (pt) |
EP (2) | EP1334106B1 (pt) |
JP (2) | JP3753971B2 (pt) |
KR (3) | KR100809899B1 (pt) |
CN (3) | CN100572363C (pt) |
AR (1) | AR034854A1 (pt) |
AT (2) | ATE327237T1 (pt) |
AU (3) | AU1429602A (pt) |
BR (1) | BR0115306B1 (pt) |
CA (1) | CA2429133C (pt) |
CY (1) | CY1105423T1 (pt) |
DE (1) | DE60119963T2 (pt) |
DK (1) | DK1334106T3 (pt) |
ES (1) | ES2260303T3 (pt) |
HK (1) | HK1056168A1 (pt) |
HU (1) | HU229408B1 (pt) |
IL (2) | IL155624A0 (pt) |
MX (1) | MXPA03004347A (pt) |
MY (1) | MY134929A (pt) |
NO (1) | NO326366B1 (pt) |
NZ (1) | NZ526387A (pt) |
PE (1) | PE20020596A1 (pt) |
PL (1) | PL204934B1 (pt) |
PT (1) | PT1334106E (pt) |
SI (1) | SI1334106T1 (pt) |
TW (1) | TWI306099B (pt) |
WO (1) | WO2002040484A2 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2275411A3 (en) * | 2002-01-10 | 2011-02-23 | Takeda Pharmaceutical Company Limited | Reformatsky Reagent in Stable Form and Process for Producing the Same |
WO2004075890A1 (ja) * | 2003-02-26 | 2004-09-10 | Takeda Pharmaceutical Company | 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾ-ル誘導体の安定化方法 |
JP4745616B2 (ja) * | 2003-02-26 | 2011-08-10 | 武田薬品工業株式会社 | 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法 |
EP1607092A4 (en) * | 2003-03-17 | 2010-12-15 | Takeda Pharmaceutical | CONTROLLED RELEASE COMPOSITIONS |
JP4837895B2 (ja) * | 2003-03-17 | 2011-12-14 | 武田薬品工業株式会社 | 放出制御組成物 |
AU2005243240B2 (en) * | 2004-05-03 | 2012-03-15 | Janssen Pharmaceutica N.V. | Novel indole derivatives as selective androgen receptor modulators (SARMS) |
EP1749005A1 (en) * | 2004-05-28 | 2007-02-07 | Speedel Experimenta AG | Tetrahydro-imidazo ¬1,5-a| pyridin derivatives as aldosterone synthase inhibitors |
JP5159303B2 (ja) | 2005-03-03 | 2013-03-06 | 武田薬品工業株式会社 | 放出制御組成物 |
GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
AR056888A1 (es) * | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
DE602007007734D1 (de) * | 2006-02-10 | 2010-08-26 | Janssen Pharmaceutica Nv | Neue imidazolopyrazolderivate als selektive androgen-rezeptor-modulatoren |
TW200804284A (en) * | 2006-03-31 | 2008-01-16 | Speedel Experimenta Ag | Process for preparing 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one |
KR20100088144A (ko) * | 2007-10-29 | 2010-08-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 공지된 암 치료법에 대해 난치성인 암의 예방 또는 치료에 사용하기 위한 피롤로 [1,2-c] 이미다졸 유도체 |
JOP20190230A1 (ar) * | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
AR083916A1 (es) * | 2010-11-18 | 2013-04-10 | Takeda Pharmaceutical | Metodo para tratar el cancer de mama y cancer de ovarios |
EP2694039B1 (en) | 2011-04-01 | 2016-09-21 | Takeda Pharmaceutical Company Limited | Solid preparation |
MX2013014009A (es) | 2011-06-15 | 2014-03-12 | Takeda Pharmaceutical | Metodo de produccion de derivados de imidazol. |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4728645A (en) * | 1982-12-21 | 1988-03-01 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors |
NZ221729A (en) | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
AU606677B2 (en) | 1987-04-22 | 1991-02-14 | Merrell Dow Pharmaceuticals Inc. | 17 beta -(cyclopropylimino) androst-5-EN-3 beta- Ol and related compounds useful as C17-20 lyase inhibitors |
US5057521A (en) * | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
US4966898A (en) | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
ATE174817T1 (de) | 1991-03-01 | 1999-01-15 | Electrostatic Technology Inc | Pulverbeschichtungsverfahren zur herstellung von leiterplatten und ähnlichen |
US5457102A (en) | 1994-07-07 | 1995-10-10 | Janssen Pharmaceutica, N.V. | Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives |
KR100263412B1 (ko) | 1992-01-27 | 2000-08-01 | 디르크 반테 | 아로마타제 억제제로서 피롤로이미다졸릴 및 이미다조피리디닐 치환된 1h-벤즈이미다졸 유도체 |
GB2265624B (en) | 1992-03-31 | 1995-04-19 | British Tech Group | 17-substituted steroids useful in cancer treatment |
GB9310635D0 (en) | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
AU679119B2 (en) | 1993-09-30 | 1997-06-19 | Yamanouchi Pharmaceutical Co., Ltd. | Azole derivative and pharmaceutical composition thereof |
AU3846395A (en) | 1994-11-07 | 1996-05-31 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
WO1997000257A1 (fr) | 1995-06-14 | 1997-01-03 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'imidazole fusionnes et composition medicinale les contenant |
EP0974584B1 (en) | 1997-02-21 | 2003-01-15 | Takeda Chemical Industries, Ltd. | Fused ring compounds, process for producing the same and use thereof |
HUP0004037A3 (en) | 1997-10-02 | 2002-03-28 | Daiichi Seiyaku Co | Novel dihydronaphthalene compounds and process for producing the same |
US6573289B1 (en) | 1998-04-23 | 2003-06-03 | Takeda Chemical Industries, Ltd. | Naphthalene derivatives, their production and use |
PE20010781A1 (es) * | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
-
2001
- 2001-11-16 AT AT01982800T patent/ATE327237T1/de active
- 2001-11-16 MX MXPA03004347A patent/MXPA03004347A/es active IP Right Grant
- 2001-11-16 IL IL15562401A patent/IL155624A0/xx active IP Right Grant
- 2001-11-16 US US10/416,986 patent/US7141598B2/en not_active Expired - Lifetime
- 2001-11-16 HU HU0400549A patent/HU229408B1/hu not_active IP Right Cessation
- 2001-11-16 SI SI200130590T patent/SI1334106T1/sl unknown
- 2001-11-16 DK DK01982800T patent/DK1334106T3/da active
- 2001-11-16 KR KR1020057018247A patent/KR100809899B1/ko active IP Right Grant
- 2001-11-16 DE DE60119963T patent/DE60119963T2/de not_active Expired - Lifetime
- 2001-11-16 CN CNB2005100640723A patent/CN100572363C/zh not_active Expired - Fee Related
- 2001-11-16 KR KR1020077025704A patent/KR20080002929A/ko not_active Application Discontinuation
- 2001-11-16 JP JP2001351035A patent/JP3753971B2/ja not_active Expired - Fee Related
- 2001-11-16 KR KR1020037006727A patent/KR100725442B1/ko active IP Right Grant
- 2001-11-16 AU AU1429602A patent/AU1429602A/xx active Pending
- 2001-11-16 PL PL362766A patent/PL204934B1/pl unknown
- 2001-11-16 CN CNB018190251A patent/CN1329394C/zh not_active Expired - Fee Related
- 2001-11-16 EP EP01982800A patent/EP1334106B1/en not_active Expired - Lifetime
- 2001-11-16 EP EP05077705.1A patent/EP1681290B9/en not_active Expired - Lifetime
- 2001-11-16 CN CNA200610100666XA patent/CN1900079A/zh active Pending
- 2001-11-16 MY MYPI20015279A patent/MY134929A/en unknown
- 2001-11-16 NZ NZ526387A patent/NZ526387A/en not_active IP Right Cessation
- 2001-11-16 PE PE2001001147A patent/PE20020596A1/es active IP Right Grant
- 2001-11-16 AT AT05077705T patent/ATE533768T1/de active
- 2001-11-16 WO PCT/JP2001/010002 patent/WO2002040484A2/en active IP Right Grant
- 2001-11-16 AU AU2002214296A patent/AU2002214296C1/en not_active Ceased
- 2001-11-16 BR BRPI0115306-4B1A patent/BR0115306B1/pt not_active IP Right Cessation
- 2001-11-16 TW TW090128440A patent/TWI306099B/zh not_active IP Right Cessation
- 2001-11-16 CA CA002429133A patent/CA2429133C/en not_active Expired - Fee Related
- 2001-11-16 AR ARP010105365A patent/AR034854A1/es active IP Right Grant
- 2001-11-16 ES ES01982800T patent/ES2260303T3/es not_active Expired - Lifetime
- 2001-11-16 PT PT01982800T patent/PT1334106E/pt unknown
-
2003
- 2003-04-28 IL IL155624A patent/IL155624A/en not_active IP Right Cessation
- 2003-05-16 NO NO20032234A patent/NO326366B1/no not_active IP Right Cessation
- 2003-11-17 HK HK03108376A patent/HK1056168A1/xx not_active IP Right Cessation
-
2005
- 2005-08-31 JP JP2005252651A patent/JP4427496B2/ja not_active Expired - Fee Related
- 2005-10-18 AU AU2005225035A patent/AU2005225035B2/en not_active Ceased
-
2006
- 2006-06-26 CY CY20061100867T patent/CY1105423T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0115306A (pt) | Composto, prodroga, composição farmacêutica, agente para diminuir androgênio, método para a produção de um composto, e, sal diastereomérico | |
PA8479201A1 (es) | Derivados del acido hidroxi-pipecolato hidroxamico | |
BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
BRPI0418004A (pt) | composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, combinação, e, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis | |
AR053162A1 (es) | Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma. | |
BR0314071A (pt) | Derivados de pró-droga de 1,3-diamino-2-hidroxipropano | |
BR9907270A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto | |
BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
AR021844A1 (es) | Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion | |
BR0312280A (pt) | Composto ou um sal, solvato, solvato de tal sal ou uma prodroga do mesmo faarmaceuticamente aceitável, processo para prepará-lo, composição farmacêutica, uso do composto, métodos para produzir um efeito inibidor da absorção de colesterol, e para tratar condições hiperlipidêmicas em um animal de sangue quente, tal como o homem, que necessita de tal tratamento, combinação, e, uso desta | |
BR0212617A (pt) | Compostos de pirazolila substituìdo para o tratamento de inflamação | |
CL2004000969A1 (es) | Compuestos derivados de alquilarilo; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de la obesidad y trastornos relacionados. | |
BR0206968A (pt) | Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como antagonistas receptores de quimiocina cxc | |
CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
BR112012015714A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença neurodegenerativa, método para reduzir a concentração de p-ser-alfa-sinucleina em tecido cerebral, e, método para o tratamento de um câncer | |
BR9911488A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto | |
BR0313723A (pt) | Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor | |
BR9909597A (pt) | Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas | |
MX9303799A (es) | Derivados de la serie de vitamina d con modificaciones en la posicon 20, procedimiento para su preparacion, productos intermedios para este procedimiento, preparados farmaceuticos que contienen estos derivados asi como su utilizacion para la prod. | |
HRP20050689A2 (en) | 4-aminopyrimidine-5-one | |
BR0206935A (pt) | Composto, formulação farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de condições associadas com a inibição da glicogênio sintase quinase-3, e, processo para a preparação de um composto | |
AR018178A1 (es) | Derivados de cromanona y tiocromanona, un proceso para su preparacion, una composicion farmaceutica que los comprende y el uso de los mismos para lapreparacion de un medicamento | |
BR0112337A (pt) | Derivados de fosfolipìdeos de ácido valpróico e suas misturas | |
MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
BR112018073219A2 (pt) | Composto de fórmula i, composição farmacêutica, processo para síntese destescompostos e uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) Free format text: ALTERADO DE: TAKEDA CHEMICAL INDUSTRIES, LTD. |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2604 DE 01-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |